Skip to content
News
Nasodine Patent Allowed in Canada

Nasodine Patent Allowed in Canada


Highlights Firebrick Pharma Limited (ASX:FRE) is pleased to announce that its core patent covering Nasodine® Nasal Spray as a treatment and preventative for the common cold has now been allowed in Canada. Once this proceeds to grant, it will bring the number of countries where this patent has been granted to 28, now covering North…

Firebrick pursues development of Nasodine for use in children

Firebrick pursues development of Nasodine for use in children


Firebrick Pharma is pleased to announce that the Paediatric Investigation Plan (PIP) for Nasodine Nasal Spray has been filed with the European Medicines Agency (EMA) Paediatric Committee (PDCO), in preparation for filing for marketing approval of Nasodine in Europe later this year. A Paediatric Investigation Plan or ‘PIP’ is a development plan aimed at ensuring…

Update on Nasodine Phase 3 trial

Update on Nasodine Phase 3 trial


Firebrick Pharma is pleased to provide an update on our Phase 3 clinical trial of Nasodine® Nasal Spray in the treatment of the common cold. As at 31 October, the trial has so far successfully recruited 224 subjects with early-stage colds into the ITT (‘Intent-To-Treat’ population), with an estimated 100 qualifying for the primary endpoint…